- Trials with a EudraCT protocol (120)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
120 result(s) found for: Treatment decision support.
Displaying page 1 of 6.
EudraCT Number: 2014-001241-24 | Sponsor Protocol Number: CFTY720D2409 | Start Date*: 2014-07-30 |
Sponsor Name:Novartis Pharma Service AG | ||
Full Title: Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod | ||
Medical condition: Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000955-25 | Sponsor Protocol Number: ClinDiab-08 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A single-centre, open-label, randomized controlled trial of efficacy, safety and usability of a basal insulin algorithm incorporated in the GlucoTab system compared to standard care for glycaemic m... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004418-27 | Sponsor Protocol Number: HS02/2014 | Start Date*: 2015-05-04 |
Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. f. Endokrinologie und Stoffwechsel | ||
Full Title: Standardized tight blood glucose management versus usual glycaemic control in patients undergoing allogeneic stem cell transplantation – a pilot trial | ||
Medical condition: Hyperglycaemic patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006251-46 | Sponsor Protocol Number: V4ByIns | Start Date*: Information not available in EudraCT |
Sponsor Name:Institute of Diabetes “Gerhardt Katsch” | ||
Full Title: Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by “Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial | ||
Medical condition: the trial will be performed in a total of 58 male and female patients with type 2 diabetes who will be assigned to two groups, receiving either exenatide or insulin glargine | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003915-11 | Sponsor Protocol Number: CarniValI (Uni-Koeln-1107) | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:University of Utah | |||||||||||||
Full Title: Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) | |||||||||||||
Medical condition: Spinal Muscular Atrophy Type I in infants | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003913-36 | Sponsor Protocol Number: REFSAL | Start Date*: Information not available in EudraCT |
Sponsor Name:Warszawski Uniwersytet Medyczny | ||
Full Title: Evaluation of frequency occurrence persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy treated by salbutamol | ||
Medical condition: Persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002024-21 | Sponsor Protocol Number: IVER-FNUSA-21 | Start Date*: 2021-06-09 | |||||||||||
Sponsor Name:Fakultní nemocnice u sv. Anny v Brně | |||||||||||||
Full Title: Randomized placebo controlled clinical trial evaluating the safety and efficacy of ivermectin in hospitalized patients with Covid-19 disease | |||||||||||||
Medical condition: Covid-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002087-12 | Sponsor Protocol Number: BN40703 | Start Date*: 2018-12-07 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY | ||||||||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005576-26 | Sponsor Protocol Number: 08-PIR-04 | Start Date*: 2009-02-19 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable L... | |||||||||||||
Medical condition: Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003904-29 | Sponsor Protocol Number: RG_16-186 | Start Date*: 2017-07-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute L... | |||||||||||||
Medical condition: Relapsed/refractory acute lymphoblatic leukaemia with mutation in the RAS pathway | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003410-12 | Sponsor Protocol Number: RG_19-169 | Start Date*: 2020-12-16 |
Sponsor Name:University of Birmingham | ||
Full Title: Pregnancy ANtihypertensive Drugs: which Agent is best? | ||
Medical condition: Hypertension in pregnancy (chronic hypertension, gestational hypertension or pre-eclampsia) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005611-31 | Sponsor Protocol Number: CORT113176-652 | Start Date*: 2022-09-07 | |||||||||||
Sponsor Name:Corcept Therapeutics Incorporated | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000778-40 | Sponsor Protocol Number: BP39056 | Start Date*: 2017-01-05 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE1 SPINAL MUSCULAR ATROPHY | |||||||||||||
Medical condition: Type 1 Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) IT (Completed) BE (Completed) FR (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002053-19 | Sponsor Protocol Number: CLMI070X2201 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Ongoing) CZ (Completed) PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006099-38 | Sponsor Protocol Number: P-piller102 | Start Date*: 2012-08-06 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study. | ||
Medical condition: Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inapprop... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003702-27 | Sponsor Protocol Number: P170929J | Start Date*: 2021-04-12 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Phase II clinical trial aiming at investigating the effect of a PARP-inhibitor on advanced metastatic breast cancer in germline PALB2 mutations carriers | ||
Medical condition: Patients with HER2 positive disease. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003480-21 | Sponsor Protocol Number: ClinDiab-03 | Start Date*: 2012-11-05 |
Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. für Endokrinologie und Stoffwechsel | ||
Full Title: An open, single-centre, non-controlled feasibility study on the performance of a tablet based workflow and decision support system with incorporated software algorithm used for glycaemic management... | ||
Medical condition: Diabetes mellitus type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005995-37 | Sponsor Protocol Number: COAV101A12306 | Start Date*: 2021-08-25 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase lllb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric pa... | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) BE (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003429-32 | Sponsor Protocol Number: ImbruVeRCHOP-Trial | Start Date*: 2017-02-09 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2” | ||
Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003933-27 | Sponsor Protocol Number: POL7080-011 | Start Date*: 2018-01-29 | |||||||||||
Sponsor Name:Polyphor Ltd. | |||||||||||||
Full Title: A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one a... | |||||||||||||
Medical condition: Ventilator-associated bacterial pneumonia (VABP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) HR (Completed) GR (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
